Evidence map›Paper›PMID 42817928›Full record

ArticlebioRxiv : the preprint server for biology2026

Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma.

Amanda G Shea, Andrew Ollendorff, Andreanna Wilke, Lei Shi, Amy K Erbe, Israrul H Ansari, Malick Bio Idrissou, Ohyun Kwon, Hansel Comas Rojas, Marta Barisa and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Amanda G SheaDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Andrew OllendorffDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Andreanna WilkeDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Lei ShiDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Israrul H AnsariDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Malick Bio IdrissouDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Ohyun KwonDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.ORCID 0000-0002-0334-105X
Hansel Comas RojasDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Marta BarisaDevelopmental Biology and Cancer Programme, University College London, Great Ormond Street Institute of Child Health, London, United Kingdom.
John AndersonDevelopmental Biology and Cancer Programme, University College London, Great Ormond Street Institute of Child Health, London, United Kingdom.
Jens C EickhoffDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Irene OngDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Rebecca M RichardsDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Paul M SondelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Christian M CapitiniDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.ORCID 0000-0002-2276-6731
Reinier HernandezDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.ORCID 0000-0002-0729-2179
Bryan P BednarzDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Jamey P WeichertDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA 53705.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.
Quaovi H SodjiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 53705.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Label-free imaging of CAR T cell metabolismR01CA278051 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Christian Capitini, Krishanu Saha · 2023 to 2026
$2.6M
Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against NeuroblastomaK08CA285941 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Quaovi H Sodji · 2024 to 2026
$479k
NCI NIH HHS K08 CA285941NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA278051
6 · The paper itself

Abstract

Background: Chimeric antigen receptor (CAR) T cell therapy has had clinical success in hematologic malignancies, but limited efficacy is seen in solid tumors. In this study, we investigated whether systemic CAR T cell therapy could be enhanced in metastatic models of neuroblastoma when combined with radiopharmaceutical therapy (RPT). Methods: Non-irradiated or irradiated tumor cells were co-cultured with CAR T cells (1:1) Results: In models of metastatic neuroblastoma, Conclusions: Our findings demonstrate that low-dose RPT can potentiate the anti-tumor efficacy of CAR T cells in metastatic neuroblastoma. To our knowledge, this is the first report of dosimetry-based RPT being combined with CAR T cells in a metastatic solid tumor setting. These findings underscore the potential of combining RPT and CAR T cells to overcome the unique challenges of solid tumors, particularly when treating metastatic disease.

Identifiers

PMID42817928
PMCPMC13622001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.